From the Editor: A Note on the 2020 Redesign
Editor-in-Chief, Dr. Laura Michaelis introduces the 2020 The Hematologist print redesign, including a better layout, more modern look, and clearer signposts within
A Novel Immunotherapy for T-ALL
Drs. Diorio and Teachey discuss the work of researchers that developed two monoclonal antibodies targeting IL-7Rα that proved effective when used separately or in combinati
Download issue as PDF
Dr. Benjamin Kim and Dr. Mark Chao discuss what it's like for a hematologist holding an industry position.
Dr. Aaron Gerds and Dr. Ruben Mesa summarize new NCCN guidelines for myeloproliferative neoplasms.
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Dr. Abdel-Wahab discusses the use of vitamin C to restore TET2 deficiency in combination with PARP inhibition in the treatment of leukemia.
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Raje and Dr. Yee cover efforts to identify new pathways to treat multiple myeloma relapse.
Dr. Moll reviews a study that looks at the use of direct oral anticoagulants, specifically apixaban, in patients on hemodyalisis.
Dr. Keel looks at a study that considers azacitidine-based combination chemotherapy as therapy for a subset of high-risk MDS patients with chronic myelomonocytic leukemia.
Dr. Linkins reviews the use of IVIg for off-label treatment of severe heparin-induced thrombocytopenia that has proven refractory to standard measures.
Dr. DeBaun reviews the risk of venous thromboembolism for children and adults with sickle cell disease.
Drs. Miles Conrad, Melissa Dickey, Steven Hetts and Andrew Leavitt discuss approaches to hereditary hemorrhagic telangiectasia.
Drs. Andrea Baines and Ann Farrell explain the process of obtaining an investigational agent outside of a clinical trial through expanded access programs.
Dr. Paneez Khoury provides an overview of the diagnosis and treatment of lymphocytic variant hypereosinophilic syndromes.
Dr. Jacobson looks at a study that investigates the safety and efficacy of chimeric antigen receptor (CAR)- T cell therapy with KTE-C19 in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory DLBCL.
Dr. Robert Peter Gale and Dr. William Fibbe pay tribute to Johannes Joseph van Rood as they shed light on the life and accomplishments of this immunohematology pioneer.
Dr. Nancy Berliner reflects on her career; former protégé Dr. Elisabeth Battinelli pays tribute to her mentor.
In his final President's Column as ASH President, Dr. Ken Anderson provides a thorough overview of ASH's research agenda including topics such as precision medicine, improving the state of care for VTE, epigenetic mechanisms, and stem cell biology and regenerative medicine.
Take this image challenge to determine the diagnosis for a 65-year-old man who presented to clinic with one week of recurrent fevers, chills and severe headaches.
Dr. Jason Gotlib, outgoing Editor-in-Chief of The Hematologist, talks about his experience as Editor-in-Chief and welcomes Dr. Laura Michaelis as the sixth Editor-in-Chief for the publication.
September-October 2019Volume 16, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology